Immune modulation permits tolerance and engraftment in a murine model of late-gestation transplantation.

In utero hematopoietic cell transplantation is an experimental nonmyeloablative therapy with potential applications in hematologic disorders, including sickle cell disease (SCD). Its clinical utility has been limited due to the early acquisition of T-cell immunity beginning at ∼14 weeks gestation, posing significant technical challenges and excluding treatment fetuses evaluated after the first trimester. Using murine neonatal transplantation at 20 days postcoitum (DPC) as a model for late-gestation transplantation (LGT) in humans, we investigated whether immune modulation with anti-CD3 monoclonal antibody (mAb) could achieve donor-specific tolerance and sustained allogeneic engraftment comparable with that of the early-gestation fetal recipient at 14 DPC.

Studies on the effect of a nutritious vegetable, on HbSS blood.

Medicinal plants have been used traditionally in Africa, especially Nigeria, in the management of sickle cell disorder (SCD) whose treatment has been mainly palliative. The antisickling properties of ethanol extract of Hook, F. (TO) (Family Cucurbitaceae) leaf was tested at concentrations 1, 2, 4, 8 and 16 mg/mL using inhibitory and reversal models.

Antimalarial, hematological, and antioxidant effects of methanolic extract of Terminalia avicennioides in Plasmodium berghei-infected mice.

Terminalia avicennioides Guill. & Perr. (Combretaceae) is used traditionally to treat malaria in Nigeria.